We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+9.7%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.59B
AUM Growth
+$300M
Cap. Flow
+$374M
Cap. Flow %
23.51%
Top 10 Hldgs %
49.78%
Holding
111
New
24
Increased
22
Reduced
23
Closed
30

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$67.1M
2
NVCR icon
NovoCure
NVCR
+$58M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$38.1M
4
AZN icon
AstraZeneca
AZN
+$28.6M
5
IART icon
Integra LifeSciences
IART
+$27.9M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$35.3M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$33.2M
3
RVMD icon
Revolution Medicines
RVMD
+$25.4M
4
TXG icon
10x Genomics
TXG
+$21.5M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$18.2M

Sector Composition

Rank Sector Weight
1 Healthcare 83.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
26
Praxis Precision Medicines
PRAX
$8.52B
$18.7M 1.18%
243,540
-15,858
-6% -$1.15M
ALNY icon
27
Alnylam Pharmaceuticals
ALNY
$29.5B
$18.1M 1.14%
76,800
+17,400
+29% +$4.58M
ADPT icon
28
Adaptive Biotechnologies
ADPT
$3.68B
$17.9M 1.12%
2,983,142
+1,870,393
+168% +$10.3M
FOCL
29
EDAP TMS S.A.
FOCL
$224M
$16.2M 1.02%
7,309,254
– –
TAK icon
30
Takeda Pharmaceutical
TAK
$52.9B
$15.6M 0.98%
1,180,000
+680,000
+136% +$9.34M
PHVS icon
31
Pharvaris
PHVS
$2.25B
$15.6M 0.98%
814,652
+216,483
+36% +$4.46M
SRDX
32
DELISTED
Surmodics
SRDX
$15.6M 0.98%
394,060
-243,638
-38% -$9.48M
SEPN
33
Septerna Inc
SEPN
$1.58B
$15.5M 0.97%
+675,409
New +$16M
MRUS
34
DELISTED
Merus
MRUS
$13.1M 0.83%
312,321
-86,000
-22% -$4.13M
OFIX icon
35
Orthofix Medical
OFIX
$496M
$12M 0.75%
686,374
+79,441
+13% +$1.38M
ANIP icon
36
ANI Pharmaceuticals
ANIP
$1.8B
$11.3M 0.71%
205,294
-63,706
-24% -$3.66M
VSTM icon
37
Verastem
VSTM
$500M
$11.3M 0.71%
2,184,026
-643,937
-23% -$2.54M
PTGX icon
38
Protagonist Therapeutics
PTGX
$8.51B
$10.6M 0.67%
+275,000
New +$12M
DCTH icon
39
Delcath Systems
DCTH
$450M
$9.64M 0.61%
+801,000
New +$8.45M
CGON icon
40
CG Oncology
CGON
$6.1B
$9.42M 0.59%
328,585
-12,000
-4% -$411K
ACLX
41
DELISTED
Arcellx
ACLX
$9.28M 0.58%
121,031
+28,000
+30% +$2.42M
LLY icon
42
Eli Lilly
LLY
$995B
$9M 0.57%
11,658
-7,642
-40% -$6.33M
RVMD icon
43
Revolution Medicines
RVMD
$38.8B
$8.8M 0.55%
201,084
-503,500
-71% -$25.4M
THTX
44
DELISTED
Theratechnologies
THTX
$8.69M 0.55%
4,801,376
– –
NUVL
45
DELISTED
Nuvalent
NUVL
$8.17M 0.51%
104,357
+30,000
+40% +$2.8M
PCVX icon
46
Vaxcyte
PCVX
$7.73B
$8.11M 0.51%
99,050
+72,000
+266% +$7.15M
EOLS icon
47
Evolus
EOLS
$398M
$7.7M 0.48%
697,158
-340,522
-33% -$4.79M
IMUX icon
48
Immunic
IMUX
$192M
$7.29M 0.46%
729,301
– –
SRRK icon
49
Scholar Rock
SRRK
$5.73B
$7.24M 0.46%
+167,543
New +$5.46M
CSTL icon
50
Castle Biosciences
CSTL
$928M
$6.74M 0.42%
252,917
-409,415
-62% -$12.5M
1
2
3 4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Soleus Capital Management held 111 positions worth $1.59B, up 23% from $1.29B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Soleus Capital Management deployed $374M of net new capital in Q4 2024, opening 24 new positions and adding to 22 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 1,001,400 shares worth $65.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 93% a quarter earlier.

On the sell side, the largest reduction was Revolution Medicines, an estimated $25.4M trimmed.

  • Soleus Capital Management's largest Q4 2024 buy was BioMarin Pharmaceuticals: 1,001,400 shares worth $65.8M.
  • Soleus Capital Management added most to Krystal Biotech in Q4 2024, an estimated $25.1M increase.
  • Soleus Capital Management's biggest Q4 2024 reduction was Revolution Medicines, cutting an estimated $25.4M.
  • Soleus Capital Management fully exited Sanofi in Q4 2024, selling an estimated $35.3M.
  • Soleus Capital Management's ten largest holdings make up 50% of its $1.59B portfolio in Q4 2024.
  • Soleus Capital Management opened 24 new positions and closed 30 in Q4 2024.
  • Soleus Capital Management's portfolio value rose 23% quarter-over-quarter to $1.59B.

Based on Soleus Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.